DexCom, Inc. (DXCM)

Market Cap	34.42B
Revenue (ttm)	4.03B
Net Income (ttm)	576.20M
Shares Out	390.77M
EPS (ttm)	1.42
PE Ratio	62.31
Forward PE	44.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,973
Open	89.45
Previous Close	89.34
Day's Range	88.28 - 88.84
52-Week Range	62.34 - 142.00
Beta	1.14
Analysts	Strong Buy
Price Target	99.06 (+12.45%)
Earnings Date	Feb 13, 2025

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 10,300
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com

Financial Performance

In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.

Analyst Forecast

According to 17 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price forecast is $99.06, which is an increase of 12.45% from the latest price.

Price Target

$99.06

(12.45% upside)

Analyst Consensus: Strong Buy